No abstract available
Keywords:
Immune-related adverse events; Immunotherapy; Myasthenia gravis; NSCLC; Thymoma.
MeSH terms
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antineoplastic Agents, Immunological / adverse effects
-
Antineoplastic Agents, Immunological / therapeutic use*
-
B7-H1 Antigen / antagonists & inhibitors
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Drug-Related Side Effects and Adverse Reactions / diagnosis*
-
Female
-
Humans
-
Lung Neoplasms / drug therapy*
-
Middle Aged
-
Myasthenia Gravis / diagnosis*
-
Myasthenia Gravis / etiology
-
Neoplasm Metastasis
-
Neoplasm Staging
-
Thymectomy
-
Thymoma / drug therapy*
-
Thymoma / surgery
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
B7-H1 Antigen
-
CD274 protein, human
-
pembrolizumab